Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart


Date Filing Description Download
02/22/17 3 Initial Statement of Beneficial Ownership
02/22/17 4 Statement of Changes in Beneficial Ownership
02/21/17 8-K Current report filing
02/14/17 SC 13G Statement of Ownership

Stock Quote

ACOR (Common Stock) $ 24.90 -0.10 (-0.4%) Volume: 416,167 MORE February 24, 2017

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *

Enter the code shown above.